LBA18 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC)

Author(s):

F. André ◽

E.M. Ciruelos ◽

D. Juric ◽

S. Loibl ◽

M. Campone ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Phase Iii ◽

Phase Iii Study ◽

Abstract PD5-12: Buparlisib (BUP) or placebo (PBO) plus fulvestrant (FUL) in postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Overall survival (OS) results from BELLE-2, a randomized, phase III study

10.1158/1538-7445.sabcs17-pd5-12 ◽

2018 ◽

Author(s):

M Campone ◽

S-A Im ◽

H Iwata ◽

M Clemons ◽

Y Ito ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Phase Iii ◽

Phase Iii Study ◽

Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib

10.1158/1538-7445.sabcs20-pd2-04 ◽

2021 ◽

Author(s):

Debu Tripathy ◽

Seock-Ah Im ◽

Marco Colleoni ◽

Fabio Franke ◽

Aditya Bardia ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Hormone Receptor ◽

Growth Factor Receptor ◽

Phase Iii ◽

Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’

Annals of Oncology ◽

10.1016/j.annonc.2021.07.011 ◽

2021 ◽

Author(s):

D.J. Slamon ◽

P. Neven ◽

S. Chia ◽

G. Jerusalem ◽

M. De Laurentiis ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Hormone Receptor ◽

Growth Factor Receptor ◽

Phase Iii ◽

Abstract OT1-1-07: A phase III study of abemaciclib (LY2835219) combined with fulvestrant in women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (MONARCH 2)

10.1158/1538-7445.sabcs14-ot1-1-07 ◽

2015 ◽

Author(s):

Antonio Llombart ◽

Masakazu Toi ◽

Suzanne R Klise ◽

Martin Frenzel ◽

Edward M Chan ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Phase Iii ◽

Her2 Breast Cancer ◽

Phase Iii Study ◽

LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.2090 ◽

2021 ◽

Vol 32 ◽

pp. S1290-S1291

Author(s):

G.N. Hortobagyi ◽

S.M. Stemmer ◽

H.A. Burris ◽

Y.S. Yap ◽

G.S. Sonke ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Hormone Receptor ◽

Growth Factor Receptor ◽

Phase Iii ◽

Faculty Opinions recommendation of Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.735552873.793559053 ◽

2019 ◽

Author(s):

Ahmad Awada

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Phase Iii ◽

Endocrine Treatment ◽

Phase Iii Study ◽

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

Annals of Oncology ◽

10.1016/j.annonc.2021.05.353 ◽

2021 ◽

Author(s):

D.J. Slamon ◽

P. Neven ◽

S. Chia ◽

G. Jerusalem ◽

M. De Laurentiis ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Hormone Receptor ◽

Growth Factor Receptor ◽

Phase Iii ◽

A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)

Annals of Oncology ◽

10.1093/annonc/mdw365.90 ◽

2016 ◽

Vol 27 ◽

pp. vi98 ◽

Author(s):

F. André ◽

B. Kaufman ◽

D. Juric ◽

E. Ciruelos ◽

H. Iwata ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Hormone Receptor ◽

Growth Factor Receptor ◽

Phase Iii ◽

Phase Iii Study ◽

Abstract OT2-01-04: SOLAR-1: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy

10.1158/1538-7445.sabcs16-ot2-01-04 ◽

2017 ◽

Author(s):

F Andre ◽

B Kaufman ◽

D Juric ◽

EM Ciruelos ◽

H Iwata ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Hormone Receptor ◽

Growth Factor Receptor ◽

Phase Iii ◽

Phase Iii Study ◽

Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps624 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS624-TPS624 ◽

Cited By ~ 9

Author(s):

Peter A. Fasching ◽

Guy Heinrich Maria Jerusalem ◽

Xavier Pivot ◽

Miguel Martin ◽

Michele De Laurentiis ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Phase Iii ◽

Endocrine Treatment ◽

Phase Iii Study ◽